Last Update07 Aug 25Fair value Increased 30%
The consensus price target for Yatharth Hospital & Trauma Care Services has been raised to ₹633.33, reflecting increased valuation expectations despite a lower net profit margin and a higher future P/E multiple.
What's in the News
- Inaugurated a new 300-bed super speciality hospital in Model Town, New Delhi, expanding group capacity to over 2,300 beds across 7 hospitals.
- Shifted corporate office to Second Floor, Sovereign Capital Gate, FC-12 Sector 16A, Noida, Gautam Buddha Nagar, Uttar Pradesh - 201301.
- Board Meeting scheduled to consider and approve Un-Audited Financial Results for Q1 ended June 30, 2025.
- Board Meeting held to consider and approve Audited Financial Results for the year ended March 31, 2025.
- Expected to report Q1 2026 results on August 6, 2025.
Valuation Changes
Summary of Valuation Changes for Yatharth Hospital & Trauma Care Services
- The Consensus Analyst Price Target has risen from ₹598.00 to ₹633.33.
- The Future P/E for Yatharth Hospital & Trauma Care Services has significantly risen from 29.41x to 35.86x.
- The Net Profit Margin for Yatharth Hospital & Trauma Care Services has fallen from 15.43% to 14.29%.
Key Takeaways
- Strong demand from urbanization, aging population, and rising insurance access is set to fuel sustained revenue growth and higher-margin specialty service expansion.
- Strategic capacity additions, technology investments, and focus on efficient payer mix are likely to enhance profitability, operational efficiency, and returns.
- Heavy regional reliance, aggressive expansion, rising costs, weak cash flows, and intensifying competition expose the company to significant operational and financial risks.
Catalysts
About Yatharth Hospital & Trauma Care Services- Owns and operates super-specialty hospitals in Delhi and Madhya Pradesh.
- Rapid urbanization and growing middle-class affluence in India are driving significant increases in patient volumes and demand for high-quality secondary and tertiary healthcare, as reflected in Yatharth's 27% YoY inpatient volume growth and strong double-digit revenue expansion; this secular shift is likely to sustain above-average topline growth for several years.
- The demographic trend of an aging population and increased prevalence of non-communicable diseases is expected to continually boost demand for chronic and complex care (e.g., oncology, cardiology), supporting the company's expansion into high-margin specialties-already delivering a 49% YoY rise in oncology revenue-thus positioning Yatharth for improving net margins and earnings quality.
- Ongoing expansion of health insurance access is increasing healthcare affordability and market size, which, together with Yatharth's payer mix optimization (reduction in government patient dependency and rising cash/private insurance share), will enlarge the addressable market and favorably impact both ARPOB (Average Revenue per Occupied Bed) and net margins.
- Aggressive capacity expansion-via new hospitals in Delhi and Faridabad and ongoing brownfield projects-combined with swift asset ramp-ups (e.g., recent facilities reaching profitability in under 12-15 months), will drive multiyear revenue, EBITDA, and earnings growth ahead of current market expectations.
- Investments in advanced medical technology, star specialist recruitment, and digitalization are enhancing both operational efficiency and brand reputation, supporting margin improvement and enabling higher occupancy/utilization rates, which together should help raise profitability and return on capital over the medium-to-long term.
Yatharth Hospital & Trauma Care Services Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Yatharth Hospital & Trauma Care Services's revenue will grow by 32.0% annually over the next 3 years.
- Analysts assume that profit margins will increase from 15.3% today to 15.6% in 3 years time.
- Analysts expect earnings to reach ₹3.3 billion (and earnings per share of ₹29.99) by about August 2028, up from ₹1.4 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as ₹2.5 billion.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 39.7x on those 2028 earnings, down from 48.3x today. This future PE is lower than the current PE for the IN Healthcare industry at 47.3x.
- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 12.73%, as per the Simply Wall St company report.
Yatharth Hospital & Trauma Care Services Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- The company's expansion strategy remains heavily concentrated in the NCR region and select Tier 2 cities, creating a risk of revenue volatility if market dynamics, regulatory changes, or competition intensify locally; this geographic overdependence may limit revenue growth and expose net margins to shocks from regional disruptions.
- Rapid bed additions and greenfield/brownfield expansions-coupled with plans to deploy ₹1,400–1,500 crore CapEx over the next three years-heighten the risk of execution delays, underutilization of new capacity, and prolonged breakeven periods, which could suppress group-level occupancy rates and dampen earnings growth.
- While a shift toward super specialty and high-complexity treatments raises ARPOB, it also results in higher employee costs (specialist doctors, staff) and greater dependency on high-value, but lower-volume, procedures; if demand for these specialties underperforms or if cost discipline weakens, net margins may come under pressure.
- Company's high trade receivable days (over 120 days) and ongoing exposure to government business-even as it aims to reduce the government payer mix-constrain cash flow conversion, increasing working capital needs and the risk of bad debts, potentially limiting available cash for reinvestment and weakening earnings quality.
- Intensifying competition in NCR from well-capitalized chains like Fortis and Max, rising regulatory scrutiny (e.g., tax investigations, empanelment delays), and acute healthcare talent shortages could erode Yatharth's competitive advantage, pressure pricing power, and push up operating expenses-collectively restraining revenue growth and net profit margins in the long term.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of ₹780.0 for Yatharth Hospital & Trauma Care Services based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be ₹21.3 billion, earnings will come to ₹3.3 billion, and it would be trading on a PE ratio of 39.7x, assuming you use a discount rate of 12.7%.
- Given the current share price of ₹712.35, the analyst price target of ₹780.0 is 8.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.